Products

BrightHeart View Classifier
BrightHeart
Cardiology AI
BrightHeart's B-Right AI Platform, including the B-Right Views tool, provides AI-powered guidance and analysis for prenatal ultrasound exams, enhancing the detection of congenital heart defects and ensuring exam completeness.

See all 1 product →

About BrightHeart

BrightHeart is a Paris-based healthcare AI company specializing in artificial intelligence solutions for obstetrics and pediatric cardiology, with a primary focus on fetal heart assessment. The company’s flagship offering is the B-Right AI Platform, an FDA-cleared and CE-marked digital screening tool designed to integrate into routine obstetric ultrasound workflows. This platform assists clinicians by guiding views, checking exam completeness, and flagging structural abnormalities suggestive of congenital heart defects (CHDs), which are the most common type of birth defect and often go undetected during prenatal ultrasounds.

BrightHeart’s technology aims to address the historically low prenatal CHD detection rates, which can be as low as 30-70% due to the complexity of the exams and the expertise required. The AI-powered software provides real-time analysis, enhancing diagnostic accuracy and streamlining clinical workflows without disrupting how clinicians typically scan. Clinically validated, BrightHeart’s technology has been shown to improve CHD detection to over 96% while reducing diagnostic errors and improving efficiency. The company emphasizes its commitment to making expert-level ultrasound care accessible, regardless of resources, setting, or expertise.

Focus Areas

prenatal ultrasound congenital heart defects (CHD) detection AI for medical imaging fetal heart screening clinical decision support obstetrics pediatric cardiology

Business Intelligence

TechnologyCloud-native, AI operating system (B-Right AI Platform)

What Physicians Need to Know

Specialization
BrightHeart specializes in AI solutions for obstetrics and pediatric cardiology, with a primary focus on fetal heart assessment and the detection of congenital heart defects (CHDs) during prenatal ultrasounds.
Key Differentiators
BrightHeart's core differentiator is its AI-powered digital screening tool that facilitates comprehensive and standardized fetal heart assessments. This technology addresses the significant challenge of CHD screening, as up to 70% of cases are currently undetected during routine prenatal ultrasounds. Their platform provides real-time AI-driven analysis directly to clinicians via a cart-side tablet, streamlining workflows and enhancing accuracy. They have also achieved multiple FDA 510(k) clearances for their B-Right Screen AI software (for flagging structural markers of CHDs) and B-Right Views (for automatically detecting and confirming required fetal heart ultrasound views).
Technology Stack
BrightHeart leverages advanced AI and machine learning, including Meta's open-source DINOv2 model. DINOv2 utilizes self-supervised learning for a deeper understanding of images and video, which aids in the early detection of CHDs.
Clinical Impact
Studies have shown BrightHeart's AI software improves CHD detection rates by 15.3% in sensitivity and boosts efficiency by cutting reading time by 18% among specialists. Their integrated solution offers real-time, comprehensive feedback on fetal heart documentation while simultaneously flagging structural markers suggestive of severe CHDs.
Physician Tip

For physicians, BrightHeart's platform offers a significant advantage by providing real-time AI analysis during fetal ultrasound exams, which can improve the accuracy and efficiency of CHD detection. The system helps ensure comprehensive and standardized fetal heart assessments, even for complex cases, by confirming that all recommended views are captured and documented. This can lead to earlier diagnosis and optimized care for babies with CHDs, ultimately improving patient outcomes. The tablet integration streamlines workflow, allowing for immediate feedback and potentially reducing the burden on clinicians.

BrightHeart's AI-driven analysis is accessible in real-time using a cart-side tablet during fetal ultrasound exams, indicating a direct integration with existing ultrasound workflows. Their platform is designed to provide an integrated solution for comprehensive feedback on fetal heart documentation and flagging potential CHDs.

Products by BrightHeart

1 product in the directory

BrightHeart View Classifier
BrightHeart
Cardiology AI
BrightHeart's B-Right AI Platform, including the B-Right Views tool, provides AI-powered guidance and analysis for prenatal ultrasound exams, enhancing the detection of congenital heart defects and ensuring exam completeness.

What the Web Says

BrightHeart (also referred to as Bright Heart Health) appears to be a company in the healthcare sector, specifically offering virtual clinics for addiction treatment. Employee reviews indicate a mixed bag of experiences, with some praising flexible work and good pay, while others criticize poor management and lack of job security. There is also a separate company, BrightHR, which is an HR and health & safety software platform, and some search results for "Brightheart" refer to a character from the Warrior Cats book series, which are not relevant to this review.

Overall: Mixed

Strengths

  • Flexible work schedules (output-based).
  • Good pay and on-time payments.
  • Supportive colleagues and kind workmates.
  • Helpful doctors and therapists for patients.
  • Growing company with efforts to support therapists (for Bright Heart Health).
  • Intuitive design and helpful support (for BrightHR).

Limitations

  • Zero job security.
  • Poor and micromanaging leadership/management.
  • Lack of employee orientation; focus on profit over employees.
  • Frustration when clients don't show up for appointments (for Bright Heart Health therapists).
  • Some managers are micromanagers.
  • Inexperienced leadership focused on profit (for Bright Heart Health).

Based on reviews from: Indeed.com, Reddit, G2, Capterra

Last updated: 2026-10-21

Videos

News, demos, and interviews about BrightHeart.

Loading videos...

Videos load interactively. If none appear, search YouTube for BrightHeart →

View all on YouTube

Press & Coverage

AuntMinnie
BrightHeart closes on $12.8M funding round
BrightHeart, a company developing AI tools for prenatal ultrasound, has secured €11 million ($12.8 million) in Series A financing to support U.S. commercialization, European expansion, and product innovation for its B-Right AI platform.
2026-01
Business Wire
BrightHeart Raises €11M Series A to Scale Expert-Level AI Platform for Prenatal Ultrasound
BrightHeart announced the closing of an €11 million Series A financing round, co-led by Odyssée Venture and GO Capital, to accelerate its mission of making AI the new standard of care in prenatal ultrasound.
2026-01
BrightHeart Press Release
BrightHeart Announces CE Mark and European Launch of its AI Platform for Prenatal Ultrasound
BrightHeart has received CE Mark approval for its B-Right AI platform, enabling its launch in the European Union market to improve prenatal ultrasound screening.
2026-07
BrightHeart Press Release
BrightHeart Announces Voluson™ Solution Store Collaboration to Deliver Expert-Level AI Support Across the Full Prenatal Ultrasound Exam
BrightHeart announced a collaboration with GE HealthCare's Voluson™ Solution Store, making its B-Right AI Platform available to deliver expert-level AI support for prenatal ultrasound exams.
2026-02
Sofinnova Partners
BrightHeart Sets New Standard in Prenatal CHD Screening with Landmark Study Published in Obstetrics & Gynecology
BrightHeart announced the publication of its landmark study in Obstetrics & Gynecology, confirming its AI software as a transformative tool in prenatal screening for congenital heart defects (CHDs).
2025-09
DAIC
BrightHeart Receives FDA Clearance for B-Right Views
BrightHeart received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second device, B-Right Views, an AI-powered tool that automatically detects standard views for fetal heart ultrasound evaluations.
2025-05
EurekAlert!
Mount Sinai obstetricians first in New York City to use FDA-cleared AI tool that enhances fetal screenings for congenital heart defects
Mount Sinai-affiliated Carnegie Imaging for Women is the first center in New York City to implement BrightHeart's FDA-cleared AI software tool to enhance fetal ultrasounds for congenital heart defects.
2025-12
Medical Device Network
BrightHeart's AI demonstrates promise in congenital heart defect detection
Two new studies show BrightHeart's AI-based software for prenatal congenital heart defect screening improved detection rates and efficiency in analyzing fetal ultrasound images.
2025-01

Frequently Asked Questions

BrightHeart provides AI-powered solutions designed to enhance the accuracy and efficiency of fetal heart screening during prenatal ultrasounds. Our technology assists in identifying potential congenital heart defects by analyzing imaging data and providing quantitative assessments. This aims to support earlier and more reliable detection of CHDs.
BrightHeart's AI seamlessly integrates with current ultrasound systems, providing real-time analysis and insights directly within the existing workflow. Our AI acts as a clinical decision support tool by flagging potential anomalies and providing comprehensive reports, empowering obstetricians and pediatric cardiologists with enhanced information for timely and informed decisions regarding patient care and further management.
BrightHeart prioritizes regulatory compliance and data security. Our products adhere to stringent medical device regulations and are designed with robust data privacy protocols, including HIPAA and GDPR compliance. We are committed to rigorous validation processes to ensure the diagnostic accuracy and safety of our AI medical imaging solutions.
BrightHeart offers flexible pricing models tailored to the needs of different healthcare institutions, including subscription-based options. We provide comprehensive technical support, including dedicated account managers, 24/7 helpdesk access, and ongoing training programs to ensure seamless integration and optimal utilization of our technology by healthcare professionals.
BrightHeart actively seeks partnerships with leading hospitals, clinics, and research institutions to further advance the field of fetal heart screening. Our long-term vision is to continuously innovate our AI technology, expand our product offerings, and establish BrightHeart as a global leader in early CHD detection, ensuring sustained company stability and impact.
BrightHeart's AI technology is specifically trained on vast datasets of fetal cardiac images, enabling it to identify subtle indicators of complex CHDs that may be challenging for the human eye to detect consistently. While specific sensitivity and specificity rates can vary based on the particular defect and study, our internal validations and ongoing clinical trials demonstrate high accuracy in aiding early and precise detection.
Currently, BrightHeart's primary focus is on enhancing early detection of CHDs. However, we are actively researching and developing future functionalities that will extend our capabilities to include longitudinal monitoring and more sophisticated risk stratification tools for fetuses with identified cardiac concerns, aiming to provide a more comprehensive solution for pediatric cardiology.

Investors

Who's funded BrightHeart.

Related Companies

Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Caption Health, formerly known as Bay Labs and now part of GE HealthCare, is a pioneering medical artificial intelligence (AI) company dedicated to expanding access to high-quality ultrasound examinations. The company’s core offering is the Caption AI platform, which utilizes AI to guide healthcare providers, including those without extensive specialized training, in acquiring and interpreting […]

Anumana is an AI-driven health technology company dedicated to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that leverage multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes FDA-cleared ECG-based algorithms, generative imaging applications, and real-time procedural support […]

Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14] […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.